NCT06099184View on ClinicalTrials.gov

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 15, 2024

Primary Completion Date

October 24, 2024

Study Completion Date

October 24, 2024

Conditions
Diabetic Macular Edema
Interventions
DRUG

EYP-1901

Intravitreal Injection

DRUG

Aflibercept 2Mg/0.05Ml Inj,Oph

Intravitreal Injection

Trial Locations (6)

16507

EyePoint Investigative Site, Erie

21740

EyePoint Investigative Site, Hagerstown

24502

EyePoint Investigative Site, Lynchburg

60439

EyePoint Investigative Site, Lemont

85020

EyePoint Investigative Site, Phoenix

89502

EyePoint Investigative Site, Reno

Sponsors
All Listed Sponsors
lead

EyePoint Pharmaceuticals, Inc.

INDUSTRY